United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion session

An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024. At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum.

“We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “Notably, our academic and industry collaborators will present initial interim efficacy data from the ADVANCE EXTENSION open label extension evaluating extended-release ralinepag for pulmonary arterial hypertension and baseline data updates for the ongoing TETON studies in idiopathic pulmonary fibrosis. We are also pleased to unveil the exciting preliminary findings from our collaboration with Tempus, a leader in artificial intelligence and precision medicine, laying the foundation for earlier identification of patients with pulmonary hypertension.”

Posters, mini-symposia, and discussion sessions include:

Mini Symposium, Sunday, May 19, 10:03 to 10:15 a.m. PT: A14 – Metabolomic Signatures of Pulmonary Hypertension Associated with Interstitial Lung Disease: A Post-hoc Analysis of the INCREASE Study. Presented by Aaron B. Waxman, M.D., Ph.D., Brigham and Women’s Hospital.

Thematic poster session, Sunday, May 19, 11:30 a.m. to 1:15 p.m. PT: A46/P829 – Pulmonary Hypertension Screening Strategies in Patients with Interstitial Lung Disease: A Survey of PHINDER Study Sites. Presented by Eric Shen, PharmD, United Therapeutics.

Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m. PT: B48/P1259 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.

Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m. PT: B48/P1260 – Study Design and Rationale for the TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.

Thematic poster session, Tuesday, May 21, 11:30 a.m. to 1:15 p.m. PT: C62/P284 – Real-World Transition and Persistence to Oral Treprostinil Therapy from Parenteral Prostacyclins in Patients with Pulmonary Arterial Hypertension. Presented by Ali Ataya, M.D., University of Florida.

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D105/410 – Clinical Improvements with Parenteral Induction Therapy in Intermediate-High Risk Patients With PAH: A Sub-Group Analysis of the EXPEDITE Study. Presented by Chad Miller, M.D., Piedmont Healthcare.

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D105/420 – Initial Long-term Data from a Phase 3 Open-label Extension Study (ROR-PH-303) Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (ADVANCE EXTENSION). Presented by Joan A. Barberà, M.D., Ph.D., Hospital Clinic de Barcelona.

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/502 – Structured EHR Data Underestimates Prevalence and Misses Large Proportions of Patients with Pulmonary Hypertension. Presented by RuiJun Chen, M.D., Tempus.

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/503 – A Novel Phenotyping Pipeline to Improve Identification of Patients with Pulmonary Hypertension in Electronic Health Records. Presented by David Vidmar, Ph.D., Tempus.

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/504 – ECG-based Machine Learning Model Identifies Patients at High Risk for Incident Pulmonary Hypertension. Presented by Greg Lee, Tempus.

Sponsored events include:

The ATS 2024 Women’s Forum, Monday, May 20, 11:45 a.m. to 1:15 p.m. PT featuring Zea Borok, M.D., ATSF, formerly of the University of Southern California; Stephanie Davis, M.D., ATSF, University of North Carolina at Chapel Hill; Sonia Buist, M.D, Oregon Health & Science University; and Obianuju Ozoh, M.D., University of Lagos.

Industry Theater, Sunday, May 19, 12:30 to 1:00 p.m. PT – Implementing Treprostinil Induction Strategies in Pulmonary Hypertension. Presented by Chad Miller, M.D., Piedmont Healthcare.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 16, 2024, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.